Write in a clean editor, then format for Current Oncology in one click — DocuGuru applies the official MDPI template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Current Oncology is a peer-reviewed journal published by MDPI, covering Cancer survivorship and care, Lung Cancer Treatments and Mutations, Global Cancer Incidence and Screening. Over its lifetime it has published 5,710 papers, which have received 79,695 citations.
| Publisher | MDPI |
|---|---|
| Reference style | Numbered (MDPI) Numbered — [1], [2] in the text 1. Smith, A.; Jones, B.; Lee, C. A Representative Article Title. Current Oncology 2023, 12, 45–58.
Formats any DOI in Current Oncology style. No sign-up. |
| Abbreviation (ISO-4) | Curr. Oncol. |
| Publishes research in | Cancer survivorship and care Lung Cancer Treatments and Mutations Global Cancer Incidence and Screening Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers |
| ISSN | 1198-0052 |
| Citation impact (2-yr) | 3.11 |
| h-index | 97 |
| i10-index | 2,137 |
| Article processing charge | $1,949 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | University of Toronto |
| Journal website | www.mdpi.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and non-small lung cancer. The US FDA has successfully…
Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Immunotherapy has now firmly established itself as a novel pillar of cancer care, from the metastatic stage to the adjuvant and neoadjuvant settings in numerous cancer types. In…
OBJECTIVE: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. METHODS OF STUDY SELECTION: We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics." DATA EXTRACTION AND SYNTHESIS: Oxaliplatin has a complicated pharmacokinetic profile, with…
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the…
Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and chemotherapy, generally with temozolomide. However, disease recurs in almost all patients. Diagnosis of progression is complex given the possibility of pseudoprogression. The Response Assessment in Neuro-Oncology criteria increase the sensitivity for detecting progression. Most patients will not be candidates for new surgery or re-irradiation,…
International Journal of Environmental Medicine
International Journal of Orofacial Myology and Myofunctional Therapy
Inventions
Journal of Ageing and Longevity
Journal of Cybersecurity and Privacy
Journal of Functional Morphology and Kinesiology
Nicotine & Tobacco Research
OUP Journal (Author-Year References)
